<DOC>
	<DOCNO>NCT01178840</DOCNO>
	<brief_summary>This comparative , open-label two-period crossover study 505 couple compare PATH Woman 's Condom FC2 female condom . California Family Health Council enroll 505 couple 375 complete period . The study provide data functional performance , vaginal semen exposure , safety , acceptability two female condom . Both partner require come clinic consent study . If member couple meet eligibility requirement , sign inform consent form enrol couple . The couple randomize one two female condom use sequence two period ( WC FC2 FC2 WC ) . For first period 2-4 week , couple ask sex without condom 4 time use first assign female condom . For second period 2-4 week , couple ask sex 4 time use second assign female condom . In first period , couple one act unprotected sex collect pre- post-coital vaginal swab . The couple also use 4 female condom assign type . They ask collect pre- post-coital vaginal swab post-coital swab condom interior . The couple complete detailed Condom Use Questionnaire together condom use . An Acceptability Questionnaire complete separately male female end study period . Couples may additional act sex period desire sex least 48 hour prior study sex act . After follow-up visit , procedure repeat 4 second assign condom type without collection vaginal swab unprotected intercourse . Each couple enrol 2-3 month , depend interval sex act . Clinicians evaluate product-relatedness AEs blind condom type use . Male partner request attend final visit , , experience adverse event , followup and/or unscheduled visit .</brief_summary>
	<brief_title>Prostate Specific Antigen ( PSA ) Acute Failure Modes Study PATH Woman 's Condom FC2 Female Condom</brief_title>
	<detailed_description>Purpose : To compare performance new female condom ( PATH Woman 's Condom ) FDA-approved female condom ( FC2 ) , assess report clinical failure vaginal PSA Design : This comparative , open-label two-period crossover study 505 couple compare PATH Woman 's Condom FC2 female condom . We enroll 505 couple California Family Health Council 375 complete period . The study provide data functional performance , vaginal semen exposure , safety , acceptability two female condom . Primary objective : To compare performance PATH Woman 's Condom ( WC ) FC2 , assess self-reported total clinical failure component ( clinical breakage , slippage , misdirection , invagination ) . Secondary objective : - To compare ability WC FC2 prevent vaginal exposure semen , indicate detection PSA within vagina - To calculate sensitivity specificity report failure use PSA gold standard presence semen - To compare acceptability WC FC2 Study Population : Healthy heterosexual couple least 18 year age low risk pregnancy STIs . Study Size : 505 couple divide multiple recruitment location one center . Study Duration : Accrual require approximately 14 month . Each couple expect complete study 2-3 month . Therefore , clinical portion study complete within approximately 17 month . Data preparation , analysis , report write expect require 7 month completion clinical portion . Treatment Regimen : The couple randomize one two condom use sequence ( WC FC2 FC2 WC ) . Four condom type use couple two 2-4 week period . For first period , one set pre- post-coital vaginal swab collect around unprotected intercourse . For coital act condom used period , pre post-coital vaginal swab post-coital condom swab collect . A Condom Use Questionnaire complete condom use . An Acceptability Questionnaire complete end period . After follow-up visit , procedure repeat second 4 condom , without collection vaginal swab unprotected intercourse . Study Center : California Family Health Council Funding Source : United States Agency International Development ( USAID ) &amp; National Institute Child Health Development ( NICHD )</detailed_description>
	<criteria>Heterosexual couple Mutual monogamy 3 month Both partner 18 year age great Using effective contraception 3 month , include hormonal method ( oral , injectable , transdermal ) , intrauterine device , contraceptive implant , male female sterilization Agree remain monogamous duration study Agree wear genital pierce jewelry use study condom Agree use sex toy drug intend enhance diminish sexual response use study condom Evidence general good health without contraindication sexual activity Couple vaginal intercourse least 4 time typical month Male partner agree ejaculate intercourse use female condom Willing able participate require protocol Exclusion criterion couple ( either partner ) Intent desire become pregnant within 3 month STIs past 6 month , include chlamydia , gonorrhea , trichomoniasis , syphilis , newly acquire HSV Couple routinely use condom due concern STIs ( 90 % sex act ) Known HIV infection At high risk HIV infection , include share injection drug needle sex someone suspect HIV ( without negative HIV test since possible exposure ) . Allergies polyurethane nitrile plastic , vaginal lubricant ( silicone Astroglide ) Recent surgery biopsy male female genitalia , within past 60 day include vulva , vagina , cervix , penis , prostate , va deferens , testis Current participation study research involve drug , device , product . ( Participation observational study exclusionary ) . Exclusion criterion female partner Positive pregnancy test Within 2 month end pregnancy Concern current pregnancy : history unprotected intercourse since last menses without consistent use contraception Use contraceptive vaginal ring ( Nuvaring ) Current use vaginal product , treatment vaginal infection Routine use diaphragm vaginal pessary Polycystic ovarian syndrome ( oligomenorrhea hirsutism prior diagnosis ) Distorted vaginal anatomy ( e.g . vaginal septum pelvic prolapse ) Exclusion criterion male partner Difficulty maintain erection achieve ejaculation last two month At high risk HIV infection , include anal sex man last year Prior prostate surgery History current prostate cancer Use medication prostate condition Hypospadias abnormal penile male urethral anatomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>female condom</keyword>
	<keyword>condom</keyword>
	<keyword>clinical failure</keyword>
	<keyword>prostate-specific antigen</keyword>
	<keyword>semen exposure</keyword>
	<keyword>acceptability</keyword>
	<keyword>Prevention semen exposure</keyword>
</DOC>